focus -WSS

focus

author：explore 2025-09-10 08:21:21 - browse：81

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Grail's uphill battle for Medicare to cover its cancer screening test

WSS

Is there an 'orca uprising'? Like orcas themselves, the answer is complex.

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

Industry veterans launch new biotech VC with $310M

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

Cuban government calls US nuclear submarine stop a 'provocative escalation'

Industry veterans launch new biotech VC with $310M

knowledge

focus

Wikipedia

Wildfire smoke exposes gaps in outdoor worker protections

Blinken talks high

After affirmative action ruling, medical educators look to 'holistic review'

KalVista pill reduced swelling 'attacks' caused by genetic disease

How to save PrEP access — and even expand it

Key House Republican on health care plans exit from Congress

How to save PrEP access — and even expand it

The dental labor crisis is a moment of opportunity

Peter Hotez and the public health issue of online harassment

Digital health funding stays low as a new reality sets in

hotspot

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

Cuban government calls US nuclear submarine stop a 'provocative escalation'

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

After half a century, Israel moves to evict squatter from his cave home on the beach

Doctors' information doesn't help them choose wisely when sick

'Revelatory' study finds a smoking impact that remains after quitting

explore

knowledge

hotspot

explore